[Studies on hepatic arterial embolization with cisplatin-chitosan-microspheres in dogs].
Cisplatin-chitosan-microspheres (CDDP-DAC-MS) was chosen as a model preparation. Pharmacokinetics, targeting and embolization effects and alteration of liver function were studied after hepatic arterial embolization in dogs with CDDP-DAC-MS, and the platinum content in plasma and liver was determined by flameless atomic absorption spectrophotometry (FAAS). The result of clinical trial was also reported. After the CDDP-DAC-MS and CDDP solution were respectively infused into hepatic artery of dogs through a 5F catheter, the plasma concentration of platinum and AUC of CDDP-DAC-MS group was lower than that of CDDP solution group, but the platinum content in hepatic tissue was 2.92 times as much as that when CDDP solution was given after 24 h. Angiograms revealed a remarkable decrease in the number of arterioles in liver, and histopathologic specimens showed nodular necrosis and hepatic cell degeneration in embolized region. The levels of GPT, GOT and ALP rose transiently after embolization and recovered to normal within 3 weeks. The clinical therapy in six liver cancer patients was successful. It would appear that CDDP-DAC-MS may be a good chemoembolization agent.
Wang
Y M
YM
Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing.
Shi
T S
TS
Pu
Y L
YL
Zhu
J G
JG
Zhao
Y L
YL
D000818:Animals; D016461:Chemoembolization, Therapeutic; D002686:Chitin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D048271:Chitosan; D002945:Cisplatin / Q000008:administration & dosage*; D004285:Dogs; D004337:Drug Carriers; D006490:Hemostatics / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy; D008863:Microspheres
D004337:Drug Carriers; D006490:Hemostatics; D002686:Chitin; D048271:Chitosan; D002945:Cisplatin